Outset Medical Q2 2026 Earnings Call Summary

1Key Financial Results and Metrics

Total Revenue: $31.6 million, up 1% year-over-year and 14% sequentially.

Product Revenue: $21.9 million, down 5% year-over-year.

Console Revenue: $9.5 million, up 6% year-over-year, exceeding expectations.

Consumable Revenue: $12.4 million, down 12% year-over-year.

Service and Other Revenue: $9.7 million, up 17% year-over-year.

Recurring Revenue: $22.1 million, down 2% year-over-year.

Non-GAAP Gross Margin: 42.2%, up over 380 basis points from the previous year.

Non-GAAP Operating Loss: $12.4 million, an improvement of 7% year-over-year.

Cash Position: $151 million at the end of the quarter, with cash use of $9.5 million in Q2.

2Strategic Updates and Business Highlights

Successful implementation of new sites, with a focus on customer satisfaction and expansion.

Established a clinical excellence team to enhance customer support and optimize the use of Tablo systems.

Signed a $40 million refresh agreement with HCA Healthcare, reinforcing long-term commitment and providing a foundation for future revenue.

Introduction of the next-generation Tablo system, with enhancements aimed at improving performance and cybersecurity.

New Executive Vice President of Commercial, Derek Elliott, is expected to drive growth through refined sales processes and customer engagement.

3Forward Guidance and Outlook

Reiterated full-year 2026 revenue guidance of $125 million to $130 million, representing growth of 5% to 9% over the previous year.

Anticipated growth primarily in the third and fourth quarters, supported by a strong commercial pipeline and contracted backlog from the HCA agreement.

4Bad News, Challenges, or Points of Concern

Consumable revenue decline of 12% is attributed to tough year-over-year comparisons and lower ordering volumes.

Product revenue decline reflects a challenging growth comparison from the prior year.

The company faces variability in capital sales, making performance less predictable.

Concerns regarding the timing of new site implementations affecting consumable revenue patterns.

5Notable Q&A Insights

Console revenue outperformance was linked to the HCA agreement and other new customer expansions, but specifics were limited due to confidentiality.

Consumable revenue decline was explained as a result of tough comparisons and not indicative of underlying issues, with expectations for recovery in the latter half of the year.

There is a recognition of seasonality affecting revenue, particularly in Q3, with Q4 typically being stronger for capital equipment sales.

Feedback on the next-gen Tablo system has been positive, with a focus on ensuring a successful rollout based on pilot phase results before a full launch. This summary encapsulates the key aspects of Outset Medical's Q2 2026 earnings call, highlighting both the positive developments and challenges faced by the company.